Group 1 - The company Fujilai (SZ 301258) announced a share buyback of 1.09 million shares, representing 1.189% of its total share capital, with a total transaction amount of approximately 37.94 million yuan [1] - The buyback was executed at a maximum price of 35.8 yuan per share and a minimum price of 33.88 yuan per share, and the total funds used for the buyback exceeded the lower limit of the buyback plan but did not exceed the upper limit [1] - As of the report date, Fujilai's market capitalization is 3.1 billion yuan [1] Group 2 - For the year 2024, Fujilai's revenue composition is heavily weighted towards pharmaceuticals, accounting for 99.19% of total revenue, while other businesses contribute only 0.81% [1]

证券代码：301258 证券简称：富士莱 公告编号：2025-066 苏州富士莱医药股份有限公司 关于回购股份实施完成暨股份变动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召 开第五届董事会第二次会议，审议通过了《关于使用自有资金回购公司股份方案 的议案》，同意公司使用自有资金通过集中竞价交易方式回购公司人民币普通股 （A 股），并在未来适宜时机用于股权激励计划或员工持股计划。本次回购股份 资金总额不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含本 数），回购价格不超过人民币 40.00 元/股（含）。回购期限自公司董事会审议通 过本次回购股份方案之日起不超过 12 个月。具体内容详见公司于 2025 年 10 月 14 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用自有资金回购公 司股份方案的公告》（公告编号：2025-053）。 截至 2025 年 11 月 20 日，公司本次回购股份事项已实施完毕，根据《深圳 证 ...

Group 1 - The company Fuji Lai (301258) responded to investor inquiries on November 12, indicating that as of November 10, 2025, the total number of shareholders is 10,653 [1]

Core Viewpoint - Recent market rumors suggest that the silicon material and component alliance has been rejected by the National Development and Reform Commission and the regulatory authority, leading to significant declines in the photovoltaic and energy storage sectors [1] Industry Summary - The China Photovoltaic Industry Association expresses confidence in the industry's ability to succeed with central government support and coordination among enterprises, while dismissing circulating rumors as false information [1] - The association emphasizes its commitment to protecting national and industry interests and plans to combat malicious actions aimed at undermining the photovoltaic sector [1] Company Summary - The "Storage and Acquisition Plan Alliance" involves leading companies in the polysilicon sector aiming to consolidate the industry by acquiring and shutting down approximately 1 million tons of production capacity, ultimately controlling capacity between 2.2 to 2.5 million tons to ensure a 60-70% operational rate [1]

Core Viewpoint - Fujilai (301258) announced a delay in the implementation of its "Annual Production of 289 Tons of Specialty Raw Materials Expansion Project" to December 31, 2026, due to extended project review processes and the need for compliance with current standards [1] Group 1: Project Delay - The delay in the project is attributed to the need for identifying and proposing modifications to existing facilities and production lines to meet current standards [1] - The company aims to ensure the technological advancement, operational stability, and long-term benefits of the project by investing additional time in technical validation and optimization [1] Group 2: Investment Adjustment - Fujilai plans to increase the total investment for the "Fujilai (Shandong) Specialty Raw Materials and Intermediates CMO/CDMO Construction Project" from 250 million yuan to 310 million yuan, utilizing excess fundraising for the additional investment [1] - The internal investment structure of the project will also be adjusted accordingly [1]

Core Points - Fujilai announced an increase in the total investment for the "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" from 250 million to 310 million yuan, utilizing excess raised funds for the additional investment [2] Group 1 - The fifth meeting of the fourth board of directors is scheduled for November 10, 2025, to review the proposal regarding the increase in construction content and additional investment amount for certain fundraising projects [2] - The internal investment structure of the Shandong project will also be adjusted as part of this proposal [2] - The proposal is subject to approval by the shareholders' meeting [2]

Core Points - Fujilai announced the postponement of the implementation schedule for its "Annual Production of 289 Tons of Specialty Raw Materials Expansion Project" to December 31, 2026 [2] - The decision was made during the fourth meeting of the fifth board of directors held on November 10, 2025, and falls within the board's approval authority, thus not requiring shareholder meeting review [2] Summary by Category - **Company Announcement** - Fujilai will hold its fifth board of directors' fourth meeting on November 10, 2025, to review the postponement of certain fundraising projects [2] - The company has adjusted the timeline for its specialty raw materials expansion project to December 31, 2026 [2] - **Project Details** - The project in question involves an annual production capacity of 289 tons of specialty raw materials [2] - The postponement is officially documented and approved by the board of directors [2]

东方证券股份有限公司 关于苏州富士莱医药股份有限公司 部分募投项目延期的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为苏州 富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱部分募投项目延期事项进行 了审慎核查，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251号）同意注册，公司首次公开 向社会公众发行人民币普通股（A股）股票2,292万股，每股面值人民币1.00元， 每股发行价格为48.30元。募集资金总额人民币110,703.60万元，扣除全部发行费 用（不含增值税）后募集资金净额人民币100,313.50万元。募集资金已于2022年3 月23日划至公司指定账户。 容诚会计师事务所（特殊普通 ...

苏州富士莱医药股份有限公司部分募投项目增加建设内容、 使用超募资金追加投资额的核查意见 东方证券股份有限公司关于 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为苏州 富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱部分募投项目增加建设内容、 使用超募资金追加投资额事项进行了审慎核查，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251号）同意注册，公司首次公开 向社会公众发行人民币普通股（A股）股票2,292万股，每股面值人民币1.00元， 每股发行价格为48.30元。募集资金总额人民币110,703.60万元，扣除全部发行费 用（不含增值税）后募集资金净额人民币100,313.50万元。募集资金已于20 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-063 苏州富士莱医药股份有限公司 关于部分募投项目增加建设内容、使用超募资金追加 投资额的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"或"富士莱"）于 2025 年 11 月 10 日召开第五届董事会第四次会议，审议通过了《关于部分募投项目增 加建设内容、使用超募资金追加投资额的议案》，同意公司拟将"富士莱（山东） 特色原料药及中间体 CMO/CDMO 建设项目"（以下简称"山东项目"）的投资 总额由 25,000.00 万元调整至 31,000.00 万元，新增投资金额使用超募资金投入， 同时对该项目内部投资结构进行调整。本次事项不涉及关联交易，保荐机构对该 事项出具了核查意见。本次事项尚需提交股东会审议。现将有关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251 号）同意注册，公司首次公开 向社会公众发行人民币普通股（A 股）股票 2, ...